Oxford Gene Technology (OGT), provider of clinical genetics and diagnostic solutions to advance molecular medicine, attracted over 100 delegates to its workshop during the recent American Society of Human Genetics Conference (ASHG 2010) in Washington, USA. Entitled “From Genomic Studies to Cytogenetics Research — An Integrated and Standardised Solution”, those present heard leading researchers talk about how OGT’s array comparative genomic hybridisation (aCGH) solutions are helping to advance research into disease and cytogenetics.
Professor Stephen Rich, Director of the University of Virginia Center for Public Health Genomics, presented details of how his group are using OGT’s Genefficiency™ aCGH technology as the basis of a pioneering study exploring the relationships between genome copy number variation and type 1 diabetes. Following this was a talk by Professor David Ledbetter, Chief Scientific Officer of Geisinger Health System, who provided updates on recent developments regarding the International Standards for Cytogenomic Arrays (ISCA) Consortium and the ISCA Database, as well as discussing recent data describing the detection of uniparental disomy (UPD) using OGT’s new CytoSure™ ISCA UPD array.
Dr Mike Evans, OGT’s CEO, who also presented at the meeting, commented: “It was a very well-received series of presentations, and very gratifying to see such interest in OGT’s work at the forefront of microarray development.” Dr Evans continued, “Our ongoing collaborations with internationally esteemed researchers and consortia, such as Professor Rich, Professor Ledbetter and ISCA, are testament to OGT’s dedication to providing outstanding microarray products and services.”
Oxford Gene Technology
